How Clinical Trial Data Sharing Platforms Can Advance the Study of Biomarkers.

J Law Med Ethics

Rebecca Li, Ph.D., is at the Vivli Center for Global Clinical Research Data and the Center for Bioethics at Harvard Medical School. Ida Sim, M.D., Ph.D., is at the Vivli Center for Global Clinical Research Data and at the University of California, San Francisco.

Published: September 2019

AI Article Synopsis

  • Data sharing platforms are ideal for biomarker research due to their diverse data types and collaborative features.
  • The current state of biomarker discovery requires new approaches to speed up the process.
  • Using platforms like Vivli can help researchers integrate and collaborate on specific classes of biomarkers effectively.

Article Abstract

Although data sharing platforms host diverse data types the features of these platforms are well-suited to facilitating biomarker research. Given the current state of biomarker discovery, an innovative paradigm to accelerate biomarker discovery is to utilize platforms such as Vivli to leverage researchers' abilities to integrate certain classes of biomarkers.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1073110519876165DOI Listing

Publication Analysis

Top Keywords

data sharing
8
sharing platforms
8
biomarker discovery
8
clinical trial
4
trial data
4
platforms
4
platforms advance
4
advance study
4
study biomarkers
4
biomarkers data
4

Similar Publications

Background: Mental health concerns have become increasingly prevalent; however, care remains inaccessible to many. While digital mental health interventions offer a promising solution, self-help and even coached apps have not fully addressed the challenge. There is now a growing interest in hybrid, or blended, care approaches that use apps as tools to augment, rather than to entirely guide, care.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the quality and reliability of YouTube videos as an educational resource about retinopathy of prematurity.

Methods: Videos were sourced from YouTube using the search terms "retinopathy of prematurity" and "premature retinopathy" with the default settings. Each video was assessed on the following metrics: views, likes, dislikes, comments, upload source, country of origin, view ratio, like ratio, and video power index.

View Article and Find Full Text PDF

The Quality-of-Care Network (QCN), launched by WHO and partners, links global and national actors across several countries to improve maternal and newborn health. We conducted a prospective qualitative study to examine how QCN in Bangladesh, Ethiopia, Malawi and Uganda facilitated learning, sharing, and innovation within and between network countries. We conducted 227 key informant interviews with QCN actors at global, national, and facility levels iteratively in two to four rounds from June 2019 to March 2022.

View Article and Find Full Text PDF

European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).

PLoS One

January 2025

European IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.

Background And Aims: Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. Integrating patient-centered measurements is essential for earlier and safer detection of disease progression. Home monitoring through e-health technologies, such as spirometry and oximetry connected to smartphone applications, holds promise for early detection of ILD progression or acute exacerbations, enabling timely therapeutic interventions.

View Article and Find Full Text PDF

Trajectory of the arterial-alveolar oxygen gradient in COPD for a decade.

PLoS One

January 2025

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.

Background: Chronic respiratory failure (CRF) is a critical complication in patients with chronic obstructive pulmonary disease (COPD) and is characterized by an increase in the arterial-alveolar oxygen gradient (A-aDO2). The long-term trajectory and prognostic significance remain unclear. This study aimed to assess the prognostic impact of A-aDO2 and elucidate its trajectory over ten years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!